Capital Stock |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Equity [Abstract] | |
Capital Stock | 5. Capital Stock
Preferred Stock
The Company has authorized a total of shares of preferred stock, par value $ per share, of which were outstanding at March 31, 2024 and December 31, 2023. The Company’s Board of Directors has the authority to issue preferred stock and to determine the rights, preferences, privileges, and restrictions, including voting rights.
Common Stock
On March 31, 2023, the Company entered into Securities Purchase Agreements, each a Purchase Agreement, with new and existing investors, the Investors, pursuant to which the Investors agreed to purchase in a private placement an aggregate of 3.1 million with a purchase price per unit of $ , the Private Placement. shares of common stock for the aggregate purchase price of approximately $
On January 18, 2023, Harvard Bioscience, Inc. converted 9,545 into shares of common stock. Series E Preferred Shares with accrued dividends of $
Warrants
The Company had 1,113,622 warrants to purchase common stock outstanding as of March 31, 2024 with a weighted-average exercise price of $4.69.
|